{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:22:36Z","timestamp":1790356956593,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.xphs.2020.06.019","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T02:02:15Z","timestamp":1593050535000},"page":"3013-3020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Drug Delivery System Targeting CD4+ T Cells for HIV-1 Latency Reactivation Towards the Viral Eradication"],"prefix":"10.1016","volume":"109","author":[{"given":"Thanapak","family":"Jaimalai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suthasinee","family":"Meeroekyai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuttee","family":"Suree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panchika","family":"Prangkio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5341","key":"10.1016\/j.xphs.2020.06.019_bib2","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","article-title":"Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy","volume":"278","author":"Finzi","year":"1997","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.xphs.2020.06.019_bib3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nm.3445","article-title":"HIV-1 persistence in CD4+ T cells with stem cell-like properties","volume":"20","author":"Buzon","year":"2014","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.xphs.2020.06.019_bib4","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1371\/journal.ppat.0030046","article-title":"ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia","volume":"3","author":"Maldarelli","year":"2007","journal-title":"PLoS Pathog"},{"issue":"6","key":"10.1016\/j.xphs.2020.06.019_bib5","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nm880","article-title":"Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells","volume":"9","author":"Siliciano","year":"2003","journal-title":"Nat Med"},{"issue":"6756","key":"10.1016\/j.xphs.2020.06.019_bib6","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/44755","article-title":"Re-emergence of HIV after stopping therapy","volume":"401","author":"Chun","year":"1999","journal-title":"Nature"},{"issue":"7408","key":"10.1016\/j.xphs.2020.06.019_bib7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/487439a","article-title":"HIV: shock and kill","volume":"487","author":"Deeks","year":"2012","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.xphs.2020.06.019_bib8","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1097\/QAD.0b013e328330342c","article-title":"The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells","volume":"23","author":"Shehu-Xhilaga","year":"2009","journal-title":"AIDS"},{"issue":"12","key":"10.1016\/j.xphs.2020.06.019_bib9","doi-asserted-by":"crossref","first-page":"5958","DOI":"10.1128\/JVI.00161-10","article-title":"Combinatorial latency reactivation for HIV-1 subtypes and variants","volume":"84","author":"Burnett","year":"2010","journal-title":"J\u00a0Virol"},{"issue":"6","key":"10.1016\/j.xphs.2020.06.019_bib10","doi-asserted-by":"crossref","first-page":"418","DOI":"10.2174\/157016210793499312","article-title":"Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency","volume":"8","author":"P\u00e9rez","year":"2010","journal-title":"Curr HIV Res"},{"issue":"2","key":"10.1016\/j.xphs.2020.06.019_bib11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/aid.2008.0191","article-title":"Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid","volume":"25","author":"Archin","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"11","key":"10.1016\/j.xphs.2020.06.019_bib12","doi-asserted-by":"crossref","first-page":"6782","DOI":"10.1074\/jbc.M807898200","article-title":"Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells","volume":"284","author":"Contreras","year":"2009","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.xphs.2020.06.019_bib13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ebiom.2017.07.019","article-title":"Vorinostat renders the replication-competent latent reservoir of human immunodeficiency virus (HIV) vulnerable to clearance by CD8 T cells","volume":"23","author":"Sung","year":"2017","journal-title":"EBioMedicine"},{"issue":"9","key":"10.1016\/j.xphs.2020.06.019_bib14","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1074\/jbc.M507213200","article-title":"Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation","volume":"281","author":"Takada","year":"2006","journal-title":"J\u00a0Biol Chem"},{"issue":"1","key":"10.1016\/j.xphs.2020.06.019_bib15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/bdrb.20104","article-title":"Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits","volume":"80","author":"Wise","year":"2007","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"issue":"2","key":"10.1016\/j.xphs.2020.06.019_bib16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrd1632","article-title":"Recent advances with liposomes as pharmaceutical carriers","volume":"4","author":"Torchilin","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.xphs.2020.06.019_bib17","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1208\/s12248-012-9329-6","article-title":"Design and characterization of novel peptide-coated lipid nanoparticles for targeting anti-HIV drug to CD4 expressing cells","volume":"14","author":"Endsley","year":"2012","journal-title":"AAPS J"},{"issue":"5","key":"10.1016\/j.xphs.2020.06.019_bib18","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.nano.2014.02.008","article-title":"\u03b1Env-decorated phosphatidylserine liposomes trigger phagocytosis of HIV-virus-like particles in macrophages","volume":"10","author":"Gramatica","year":"2014","journal-title":"Nanomedicine"},{"issue":"2","key":"10.1016\/j.xphs.2020.06.019_bib19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jconrel.2011.02.023","article-title":"Cell derived liposomes expressing CCR5 as a new targeted drug-delivery system for HIV infected cells","volume":"151","author":"Bronshtein","year":"2011","journal-title":"J\u00a0Control Release"},{"issue":"2","key":"10.1016\/j.xphs.2020.06.019_bib20","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.antiviral.2009.08.003","article-title":"Sustained and specific in\u00a0vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes","volume":"84","author":"Clayton","year":"2009","journal-title":"Antiviral Res"},{"issue":"1-2","key":"10.1016\/j.xphs.2020.06.019_bib21","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0005-2736(00)00254-6","article-title":"Sterically stabilized liposomes bearing anti-HLA-DR antibodies for targeting the primary cellular reservoirs of HIV-1","volume":"1468","author":"Bestman-Smith","year":"2000","journal-title":"Biochim Biophys Acta"},{"issue":"1-2","key":"10.1016\/j.xphs.2020.06.019_bib22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ijpharm.2012.04.054","article-title":"Investigation on the stability of saquinavir loaded liposomes: implication on stealth, release characteristics and cytotoxicity","volume":"431","author":"Ramana","year":"2012","journal-title":"Int J Pharm"},{"issue":"4","key":"10.1016\/j.xphs.2020.06.019_bib23","doi-asserted-by":"crossref","first-page":"e18270","DOI":"10.1371\/journal.pone.0018270","article-title":"Activation of latent HIV using drug-loaded nanoparticles","volume":"6","author":"Kovochich","year":"2011","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.xphs.2020.06.019_bib24","doi-asserted-by":"crossref","first-page":"7723","DOI":"10.1021\/nn5002694","article-title":"Bioengineered vaults: self-assembling protein shell-lipophilic core nanoparticles for drug delivery","volume":"8","author":"Buehler","year":"2014","journal-title":"ACS Nano"},{"issue":"6","key":"10.1016\/j.xphs.2020.06.019_bib25","doi-asserted-by":"crossref","first-page":"e11160","DOI":"10.1371\/journal.pone.0011160","article-title":"Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner","volume":"5","author":"Mehla","year":"2010","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.xphs.2020.06.019_bib26","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1093\/emboj\/cdg188","article-title":"HIV reproducibly establishes a latent infection after acute infection of T cells in\u00a0vitro","volume":"22","author":"Jordan","year":"2003","journal-title":"EMBO J"},{"key":"10.1016\/j.xphs.2020.06.019_bib27","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1742-4690-6-52","article-title":"\u201cShock and kill\u201d effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence","volume":"6","author":"Savarino","year":"2009","journal-title":"Retrovirology"},{"issue":"4","key":"10.1016\/j.xphs.2020.06.019_bib28","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/QAD.0b013e328333bfa1","article-title":"Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1","volume":"24","author":"Choi","year":"2010","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.xphs.2020.06.019_bib29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4049\/jimmunol.142.2.431","article-title":"Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone","volume":"142","author":"Clouse","year":"1989","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.xphs.2020.06.019_bib30","doi-asserted-by":"crossref","first-page":"24100","DOI":"10.1038\/srep24100","article-title":"The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb","volume":"6","author":"Lu","year":"2016","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.xphs.2020.06.019_bib31","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1172\/JCI80142","article-title":"Ex\u00a0vivo analysis identifies effective HIV-1 latency-reversing drug combinations","volume":"125","author":"Laird","year":"2015","journal-title":"J\u00a0Clin Invest"},{"issue":"12","key":"10.1016\/j.xphs.2020.06.019_bib32","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1039\/c2ay25480h","article-title":"Engineering liposomes as detection reagents for CD4+ T-cells","volume":"4","author":"Edwards","year":"2012","journal-title":"Anal Methods"},{"issue":"2","key":"10.1016\/j.xphs.2020.06.019_bib33","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejpb.2010.11.015","article-title":"Uptake and permeability studies of BBB-targeting immunoliposomes using the hCMEC\/D3 cell line","volume":"77","author":"Markoutsa","year":"2011","journal-title":"Eur J Pharm Biopharm"},{"issue":"7","key":"10.1016\/j.xphs.2020.06.019_bib34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.tibtech.2011.03.001","article-title":"Cancer theranostics: the rise of targeted magnetic nanoparticles","volume":"29","author":"Cole","year":"2011","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.xphs.2020.06.019_bib35","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2147\/IJN.S14615","article-title":"AFM, ESEM, TEM, and CLSM in liposomal characterization: a comparative study","volume":"6","author":"Ruozi","year":"2011","journal-title":"Int J Nanomedicine"},{"issue":"4","key":"10.1016\/j.xphs.2020.06.019_bib36","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3109\/10837451003774401","article-title":"Effect of preparation method and cholesterol on drug encapsulation studies by phospholipid liposomes","volume":"16","author":"Cagdas","year":"2011","journal-title":"Pharm Dev Technol"},{"key":"10.1016\/j.xphs.2020.06.019_bib37","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1038\/srep05005","article-title":"Cholesterol level affects surface charge of lipid membranes in saline solution","volume":"4","author":"Magarkar","year":"2014","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.xphs.2020.06.019_bib38","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1002\/jps.23265","article-title":"Vorinostat with sustained exposure and high solubility in poly(ethylene glycol)-b-poly(DL-lactic acid) micelle nanocarriers: characterization and effects on pharmacokinetics in rat serum and urine","volume":"101","author":"Mohamed","year":"2012","journal-title":"J\u00a0Pharm Sci"},{"issue":"25","key":"10.1016\/j.xphs.2020.06.019_bib39","doi-asserted-by":"crossref","first-page":"22211","DOI":"10.1074\/jbc.M110.180224","article-title":"Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells","volume":"286","author":"Huber","year":"2011","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.xphs.2020.06.019_bib40","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.virol.2018.05.006","article-title":"Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents","volume":"520","author":"Marsden","year":"2018","journal-title":"Virology"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354920303324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354920303324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:29:53Z","timestamp":1758360593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354920303324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0022354920303324"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2020.06.019","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug Delivery System Targeting CD4+ T Cells for HIV-1 Latency Reactivation Towards the Viral Eradication","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2020.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}